Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 26, 2023
DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION USING WRISTBAND SENSOR
-
December 18, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TASURGRATINIB FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION
-
December 13, 2023
番茄影视 and Mizuho Sign Sustainability-Linked Loan Agreement
-
December 13, 2023
鈥淟EQEMBI庐 Intravenous Infusion鈥� (Lecanemab) for the Treatment of Alzheimer鈥檚 Disease to be Launched in Japan on December 20
-
December 9, 2023
番茄影视 and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
-
November 30, 2023
EISAI鈥橲 SALES SUBSIDIARY COLLABORATES WITH MINISTRY OF PUBLIC HEALTH (MOPH) IN THAILAND
-
November 22, 2023
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 77TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
-
November 20, 2023
LEQEMBI庐 Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023
-
November 16, 2023
EISAI NAMED AS 鈥淕REATEST IR IMPROVEMENT PREMIUM COMPANY鈥� AND 鈥淏EST CONTINUAL IR EFFORTS PREMIUM COMPANY鈥� AT THE JAPAN INVESTOR RELATIONS ASSOCIATION 30TH ANNIVERSARY COMMEMORATIVE AWARDS
-
October 26, 2023
EISAI PRESENTS NEW LEQEMBI庐 (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER鈥橲 DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE (CTAD) CONFERENCE
INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV
76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL IMPROVEMENT AT 18 MONTHS IN LOW-TAU SUBPOPULATION IN ADDITIONAL ANALYSIS OF CLARITY AD
DUAL-ACTING LEQEMBI SUPPORTS BRAIN NEURON FUNCTION BY REMOVING HIGHLY TOXIC PROTEINS (PROTOFIBRILS) THAT CAN CONTINUE TO CAUSE NEURONAL INJURY AND DEATH EVEN AFTER PLAQUE REMOVAL, OFFERING EARLY AD PATIENTS THE OPPORTUNITY FOR CONTINUED BENEFIT
-
October 25, 2023
LEQEMBI庐 (LECANEMAB-IRMB) NAMED ONE OF TIME鈥橲 BEST INVENTIONS OF 2023
-
October 16, 2023
EISAI TO PRESENT NEW DATA FROM LEQEMBI庐 (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER鈥橲 DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Update on LEQEMBI Investigational Subcutaneous Formulation
-
October 11, 2023
EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO CONGRESS 2023
-
October 4, 2023
Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
-
September 28, 2023
EISAI LAUNCHES NEW 鈥淚NNOVATION鈥� PAGE ON CORPORATE WEBSITE
-
September 28, 2023
TOKIO MARINE NICHIDO AND EISAI
CO-DEVELP INDUSTRY鈥橲 FIRST 鈥淒EMENTIA CARE SUPPORT INSURANCE鈥�
-
September 25, 2023
鈥淟EQEMBI庐 Intravenous Infusion鈥� (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in Japan
-
September 22, 2023
番茄影视 and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Two Phase 3 Trials Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
-
September 21, 2023
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER鈥橲 DAY, SEPTEMBER 21
LIFE GOES ON 2023: TWO MEMORIES, ONE STORY
LEARNING HELPS US TO BE KIND
-
September 12, 2023
EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM
-
August 25, 2023
番茄影视 and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-010 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
-
August 4, 2023
EISAI LISTED FOR 22ND CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
August 1, 2023
ORGANIZATIONAL REFORM AND CHANGES OF CORPORATE OFFICERS
-
July 20, 2023
番茄影视 Presents Latest Analysis of Lecanemab鈥檚 Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer鈥檚 Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer鈥檚 disease
New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option for administering therapy
-
July 12, 2023
EISAI TO PRESENT THE LATEST ALZHEIMER鈥橲 DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
-
July 11, 2023
CHANGES OF CORPORATE OFFICERS
-
July 7, 2023
FDA Grants Traditional Approval for LEQEMBI庐 (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer鈥檚 disease
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI
-
June 30, 2023
EISAI TRANSFERS ALL FUTURE ECONOMIC RIGHTS FOR ELACESTRANT, A SELECTIVE ESTROGEN RECEPTOR DEGRADER, TO DRI HEALTHCARE
-
June 29, 2023
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
-
June 29, 2023
NEW NEURII RESEARCH COLLABORATION BETWEEN EISAI, GATES VENTURES, HEALTH DATA RESEARCH UK, LIFEARC AND THE UNIVERSITY OF EDINBURGH TO DEVELOP DIGITAL SOLUTIONS FOR DEMENTIA IS ANNOUNCED
-
June 22, 2023
EISAI鈥橲 鈥淣OUKNOW庐鈥� WILL CONTINUE TO BE UTILIZED FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2023 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2022 PAY FOR SUCCESS CONTRACT
-
June 10, 2023
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI庐 (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer鈥檚 disease
The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review
LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer鈥檚 disease on January 6, 2023
-
June 8, 2023
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE IN SOUTH KOREA
-
June 6, 2023
Notification of Ransomware Incident
-
June 2, 2023
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 37TH ANNUAL SLEEP 2023 MEETING
-
May 26, 2023
LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
After four years of follow-up, LENVIMA plus KEYTRUDA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial
Final results will be presented at ASCO 2023 in an oral abstract session
-
May 25, 2023
EISAI鈥橲 INITIATIVES FOR DEVELOPING NEW MEDICINES FOR NEGLECTED TROPICAL DISEASES AND MALARIA AND COMMITMENT FOR FUNDING TO THE 3RD PHASE OF GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND ACTIVITIES
-
May 24, 2023
EISAI DELIVERS NEW DATA AND HIGHLIGHTS CONTINUED PROGRESS OF ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
-
May 22, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE IN GREAT BRITAIN
-
May 17, 2023
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB IN JAPAN USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
-
May 16, 2023
HEALTH CANADA ACCEPTS NEW DRUG SUBMISSION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE
-
May 15, 2023
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Revision of the Stock Compensation System (Officers鈥� Compensation BIP Trust)
-
May 15, 2023
Notification Regarding the Revision of the Compensation System for Directors and Corporate Officers and Stock Compensation System (Officers鈥� Compensation BIP Trust) and Additional Contribution
-
May 9, 2023
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2023
-
May 8, 2023
EISAI ENTERS INTO JOINT DEVELOPMENT AGREEMENT WITH BLISSBIO FOR ANTIBODY DRUG CONJUGATE BB-1701 WITH OPTION RIGHTS FOR STRATEGIC COLLABORATION
-
April 7, 2023
番茄影视 and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 Trials of LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
-
April 6, 2023
EISAI COMPLETES A MAJOR RENOVATION OF TSUKUBA RESEARCH LABORATORIES
AS A GLOBAL DRUG DISCOVERY CENTER AIMING FOR CONNECTING HUMAN AND HUMAN, AND DATA, AND THE WORLD
-
April 4, 2023
EISAI PUBLISHES LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Treatment with Lecanemab Resulted in a Delay of 2 to 3 Years in the Mean Time to Progression to More Severe Stages of Alzheimer鈥檚 Disease, Compared with Standard of Care Alone
Subgroup Analysis Suggested that Earlier Initiation of Treatment with Lecanemab May Have a Greater Impact on Disease Progression
-
April 3, 2023
EISAI ENTERS INTO AGREEMENT WITH NATIONAL CANCER CENTER TO COLLABORATE ON INVESTIGATOR-INITIATED CLINICAL RESEARCH FOR ANTICANCER AGENT TAZEMETOSTAT BASED ON 鈥淧ATIENT-PROPOSED HEALTHCARE SERVICES鈥� SYSTEM
-
March 31, 2023
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD鈩� 2023 ANNUAL MEETING
-
March 31, 2023
ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
-
March 24, 2023
EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY (SGO) 2023 ANNUAL MEETING ON WOMEN鈥橲 CANCER
-
March 23, 2023
EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVALUATING SAFETY PROFILE, CLINICAL OUTCOMES AND QUALITY OF LIFE MEASURES, AS WELL AS OTHER IMPORTANT ALZHEIMER鈥橲 DISEASE RESEARCH, AT THE AD/PD鈩� 2023 ANNUAL MEETING
Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from 番茄影视鈥檚 Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer鈥檚 Disease
-
March 20, 2023
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
-
March 14, 2023
U.S. VETERANS鈥� HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI鈩� (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI鈥橲 FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER鈥橲 DISEASE
EISAI IS PROUD TO SUPPORT U.S. VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER鈥橲 DISEASE AND WILL CONTINUE TO TRANSPARENTLY SHARE OUR HIGH-QUALITY DATA WITH THE VHA
-
March 10, 2023
EISAI RECEIVES THE 鈥淏ASIC ACHIEVEMENT GRAND PRIZE鈥� AT THE 2023 J-WIN DIVERSITY AWARD
-
March 9, 2023
EISAI CERTIFIED AS A 2023 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)
-
March 6, 2023
FDA Accepts 番茄影视鈥檚 Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI鈩� (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval
Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023
-
March 2, 2023
BIOGEN JAPAN AND EISAI PROVIDE UPDATE ON CO-PROMOTION OF MULTIPLE SCLEROSIS TREATMENTS IN JAPAN
-
February 28, 2023
BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
-
February 20, 2023
DISSOLUTION OF BRACCO-EISAI JOINT VENTURE
-
January 30, 2023
LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
-
January 27, 2023
MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY
-
January 19, 2023
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN ISRAEL
-
January 18, 2023
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 18, 2023
EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023
Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer
Research from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma
-
January 16, 2023
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER鈥橲 DISEASE IN JAPAN
-
January 13, 2023
EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE
-
January 11, 2023
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE IN EUROPE
-
January 7, 2023
番茄影视 Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI鈩� (lecanemab-irmb) for the Treatment of Alzheimer鈥檚 Disease
Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial
-
January 7, 2023
番茄影视鈥檚 Commitment to Scientific Evidence and Patient Safety
-
January 7, 2023
EISAI鈥橲 APPROACH TO U.S. PRICING FOR LEQEMBI鈩� (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER鈥橲 DISEASE, SETS FORTH OUR CONCEPT OF 鈥淪OCIETAL VALUE OF MEDICINE鈥� IN RELATION TO 鈥淧RICE OF MEDICINE鈥�
MAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY
-
January 7, 2023
FDA Approves LEQEMBI鈩� (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer鈥檚 Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI鈩�
Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials
